Every material Form 8-K SANUWAVE Health, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
SANUWAVE Health amended its September 25, 2025 credit agreement with JPMorgan Chase Bank, N.A. as administrative agent. Lenders waived any default from the company's fixed charge coverage ratio for the twelve months ending September 30, 2026, which was below the level the agreement requires. The amendment also requires lender written consent for certain acquisitions and equity repurchases and lowers two basket limits, so shareholders face tighter restrictions on the company's financial flexibility.
Lenders waived any default or event of default tied to the fixed charge coverage ratio for the twelve-month period ending September 30, 2026, which was below the required level
Written lender consent is now required for Permitted Acquisitions or Restricted Payments used to repurchase outstanding equity, subject to exceptions in the amendment
Permitted other secured indebtedness and permitted subsidiary investments were each lowered from $500,000 to $250,000
The company agreed to pay a $5,000 amendment fee; the amendment is dated October 28, 2026 and filed as Exhibit 10.1
SANUWAVE Health received a Nasdaq notice on September 23, 2026, because its Market Value of Listed Securities was below $50 million for 30 consecutive business days, the minimum for continued listing on The Nasdaq Global Market. The notice has no immediate effect on the listing, but if the company does not regain compliance by March 22, 2027, it will receive a delisting notice, and the company cannot guarantee it will keep its listing.
Nasdaq notice received September 23, 2026, citing Listing Rule 5450(b)(2)(A)
Company must close at or above $50 million MVLS for 10 consecutive business days to regain compliance
Compliance period runs 180 calendar days from the notice, until March 22, 2027
Company may consider transferring to The Nasdaq Capital Market if it meets that market's requirements
Sanuwave reported second-quarter 2026 revenue of $9.7 million, down 3% from $10.1 million a year earlier, and a net loss of $0.7 million compared with net income of $0.6 million in the prior-year quarter. The company withdrew its fiscal 2026 guidance, which it says should no longer be relied upon, citing Medicare reimbursement developments and will not issue new guidance until it has more clarity, expected after CMS publishes its final rule in the fourth quarter of 2026.
Q2 2026 revenue was $9.7 million, down 3% from $10.1 million in Q2 2025; gross margin was 76.2% versus 78.1%
Net loss was $0.7 million, or $(0.08) per share, versus net income of $0.6 million in Q2 2025
Adjusted EBITDA was $1.2 million versus $3.2 million a year earlier; 82 Ultramist systems were sold versus 116 in Q2 2025
Fiscal 2026 guidance withdrawn; no new guidance until CMS publishes its final rule, anticipated in Q4 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SANUWAVE Health, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →